文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

关于单克隆抗体在癌症治疗中应用的综合综述。

A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy.

作者信息

Justiz-Vaillant Angel, Pandit Bijay Raj, Unakal Chandrashekhar, Vuma Sehlule, Akpaka Patrick Eberechi

机构信息

Department of Pathology/Microbiology & Pharmacology, The University of the West Indies, St. Augustine Campus, St. Augustine 330912, Trinidad and Tobago.

出版信息

Antibodies (Basel). 2025 Apr 11;14(2):35. doi: 10.3390/antib14020035.

DOI:10.3390/antib14020035
PMID:40265416
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12015915/
Abstract

Monoclonal antibodies (mAbs) targeting various pathways in cancer therapy play crucial roles in enhancing the immune system's ability to recognise and eliminate tumour cells. These therapies are designed to either block inhibitory immune checkpoint pathways or to target specific tumour cell markers for direct destruction. Additionally, mAbs can modulate the tumour microenvironment, enhance antibody-dependent cellular cytotoxicity, and inhibit angiogenesis, further amplifying their therapeutic impact. Below is a summary of monoclonal antibodies targeting key pathways, along with their indications and mechanisms of action, which are reviewed based on therapeutic mechanisms.

摘要

靶向癌症治疗中各种途径的单克隆抗体（mAb）在增强免疫系统识别和消除肿瘤细胞的能力方面发挥着关键作用。这些疗法旨在阻断抑制性免疫检查点途径或靶向特定肿瘤细胞标志物以进行直接破坏。此外，单克隆抗体可调节肿瘤微环境，增强抗体依赖性细胞毒性，并抑制血管生成，进一步扩大其治疗效果。以下是靶向关键途径的单克隆抗体的总结，以及它们的适应症和作用机制，这些内容基于治疗机制进行了综述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd1/12015915/f3794f777140/antibodies-14-00035-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd1/12015915/aa772008218a/antibodies-14-00035-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd1/12015915/4a4296c21389/antibodies-14-00035-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd1/12015915/de925121dddd/antibodies-14-00035-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd1/12015915/047c6a1d854e/antibodies-14-00035-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd1/12015915/d4f8b7da084e/antibodies-14-00035-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd1/12015915/f3794f777140/antibodies-14-00035-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd1/12015915/aa772008218a/antibodies-14-00035-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd1/12015915/4a4296c21389/antibodies-14-00035-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd1/12015915/de925121dddd/antibodies-14-00035-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd1/12015915/047c6a1d854e/antibodies-14-00035-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd1/12015915/d4f8b7da084e/antibodies-14-00035-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd1/12015915/f3794f777140/antibodies-14-00035-g006.jpg

相似文献

[1]
A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy.

Antibodies (Basel). 2025-4-11

[2]
Tight Interplay Between Therapeutic Monoclonal Antibodies and the Tumour Microenvironment in Cancer Therapy.

Adv Exp Med Biol. 2020

[3]
Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview.

Med Oncol. 2023-12-29

[4]
Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB.

Front Immunol. 2023

[5]
Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer.

Curr Top Microbiol Immunol. 2014

[6]
Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies.

Front Oncol. 2022-6-24

[7]
Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review.

Front Oncol. 2023-8-23

[8]
The therapeutic value of monoclonal antibodies directed against immunogenic tumor glycoproteins.

J Cancer. 2010-11-3

[9]
Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors.

Curr Opin Immunol. 2015-1-7

[10]
Monoclonal antibodies in clinical oncology.

Anticancer Agents Med Chem. 2008-6

引用本文的文献

[1]
Microenvironment and Tumor Heterogeneity as Pharmacological Targets in Precision Oncology.

Pharmaceuticals (Basel). 2025-6-18

本文引用的文献

[1]
Zenocutuzumab: First Approval.

Drugs. 2025-4

[2]
Dynamic changes in peripheral blood immunophenotyping and its prognostic value in cervical cancer patients undergoing immune checkpoint blockade therapy.

Discov Oncol. 2025-2-12

[3]
Sex differences in anti-EBV antibody responses.

J Infect Dis. 2025-2-11

[4]
The association between Chlamydia pneumoniae infection and prognosis in lung cancer patients: a prospective study.

BMC Infect Dis. 2025-1-25

[5]
Mucosal immune response in biology, disease prevention and treatment.

Signal Transduct Target Ther. 2025-1-8

[6]
Personalized cancer vaccine design using AI-powered technologies.

Front Immunol. 2024

[7]
Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions.

Front Immunol. 2024

[8]
Efficacy and Safety of Amivantamab in Advanced or Metastatic EGFR-Mutant Non-Small Cell Lung Cancer: A Systematic Review.

J Clin Med. 2024-9-16

[9]
Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy.

Biomedicines. 2024-9-23

[10]
Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges.

Mol Biotechnol. 2024-9-2

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索